Sign in

    Subbu Nabi

    Vice President and Senior Equity Analyst at Guggenheim Partners

    Subbu Nabi is a Vice President and Senior Equity Analyst at Guggenheim Partners, specializing in healthcare and biotechnology research with coverage of innovative diagnostics companies such as GRAIL. He is known for providing in-depth analysis and insights into clinical trial developments, market opportunities, and financial performance within the biotech sector. Nabi began his career in equity research and has developed a strong reputation for his rigorous approach, although definitive performance metrics, such as TipRanks rankings or published success rates, are not publicly available. He holds advanced professional credentials, including FINRA registration and relevant securities licenses, supporting his expertise in equity analysis and investment research.

    Subbu Nabi's questions to GRAIL (GRAL) leadership

    Subbu Nabi's questions to GRAIL (GRAL) leadership • Q4 2024

    Question

    An associate on behalf of Subbu Nabi inquired about the definition of success for the PATHFINDER 2 study, asking about key endpoints and performance expectations. A follow-up question sought any new details on the company's long-term cash position.

    Answer

    President Dr. Joshua Ofman explained that PATHFINDER 2's success will be measured by traditional test performance metrics like specificity, sensitivity, and predictive values, as well as safety measures. He noted the results will be part of the final modular PMA submission to the FDA in the first half of 2026. CFO Aaron Freidin reiterated that there is no change to the company's cash runway, which extends into 2028, following the restructuring completed in 2024.

    Ask Fintool Equity Research AI